PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-?B VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNEDISEASES

摘要

This invention is directed to the treatment of inflammatory and autoimmunediseases by administering proteasome inhibitors, ubiquitin pathway inhibitors,agents that interfere with the activation of NF-B via the ubiquitin proteasomepathway, or mixtures thereof. The invention is further directed to thetreatment of inflammatory and autoimmune diseases by administering aneffective combination of a glucocorticoid and a proteasome inhibitor,ubiquitin pathway inhibitor, agent that interferes with the activation of NF-Bvia the ubiquitin proteasome pathway, or mixture thereof. Pharmaceuticalcompositions comprising a combination of a glucocorticoid and a proteasomeinhibitor, ubiquitin pathway inhibitor, agent that interferes with theactivation of NF-B via the ubiquitin proteasome pathway, or mixture thereofare also contemplated within the scope of the invention.